Form 4: Crinetics Pharmaceuticals' Chief Scientific Officer Sells 3,000 Shares

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on August 26, 2024, at a price of $53.19 per share.

Summary

• On August 26, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of the company's common stock.
• The sale was executed at a price of $53.19 per share.
• Following the transaction, Betz directly owns 69,611 shares of Crinetics Pharmaceuticals.
• The sale was conducted automatically under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan and doesn't necessarily reflect a change in the executive's outlook on the company.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. However, sales under a 10b5-1 plan are less likely to be indicative of management sentiment, as they are pre-arranged.

Stakeholder Impact

• The sale of shares by a company officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates